BNP Paribas Financial Markets
MLYS icon

BNP Paribas Financial Markets’s Mineralys Therapeutics MLYS Stock Holding History

BNP Paribas Financial Markets’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303K Sell
11,242
-5,474
-33% -$150K ﹤0.01% 4027
2026
Q1 		$453K Sell
16,716
-156,213
-90% -$4.58M ﹤0.01% 3646
2025
Q4 		$6.28M Sell
172,929
-453,219
-72% -$18.2M ﹤0.01% 1893
2025
Q3 		$23.7M Buy
626,148
+622,040
+15,142% +$13.5M 0.01% 1021
2025
Q2 		$55.6K Sell
4,108
-57,085
-93% -$827K ﹤0.01% 4222
2025
Q1 		$972K Buy
61,193
+57,298
+1,471% +$659K ﹤0.01% 2809
2024
Q4 		$47.9K Buy
+3,895
New +$50.9K ﹤0.01% 4450

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM

BNP Paribas Financial Markets's MLYS Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Mineralys Therapeutics (MLYS) stake by 33% in Q2 2026, selling an estimated $150K and leaving 11,242 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #4027.

BNP Paribas Financial Markets first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. The position peaked at $23.7M in Q3 2025. 201 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • BNP Paribas Financial Markets held 11,242 shares of Mineralys Therapeutics worth $303K as of Q2 2026.
  • BNP Paribas Financial Markets sold 5,474 Mineralys Therapeutics shares in Q2 2026, an estimated $150K.
  • Mineralys Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4027 holding.
  • BNP Paribas Financial Markets first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Mineralys Therapeutics position peaked at $23.7M in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.